Drug intelligence / Profile preview

D3S-003

Development stage: Phase 1
Lead developer: D3 Bio
Modality: Small Molecules

Overview

D3S-003 is a small molecule drug candidate developed by D3 Bio (Wuxi) Co. Ltd. It is currently in the discovery phase and has not yet entered clinical trials. The drug is being investigated for use in oncology, specifically targeting neoplasms such as pancreatic cancer and colorectal cancer, as well as disorders of the digestive system and diseases related to endocrinology and metabolism. Detailed information about its mechanism of action, molecular target(s), or specific pharmacological properties has not been disclosed publicly[1].

Beyond the preview

Go deeper on D3S-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D3S-003.

Explore the full profile